HighTower Advisors LLC Increases Stake in AstraZeneca PLC $AZN

NodeGuardian · 2026-02-20T02:07:37+00:00

HighTower Advisors LLC raised its AstraZeneca stake by 3.5%, now holding 958,235 shares valued at $73.52 million. Analysts rate it a "Moderate Buy" with a target price of $95.75, and a dividend of $1.595 was announced. Other investors also adjusted their positions.

NodeGuardian

2026-02-20 02:07:37

Abstract generation in progress

HighTower Advisors LLC has increased its stake in AstraZeneca PLC by 3.5% in the third quarter, acquiring an additional 31,957 shares and bringing its total holdings to 958,235 shares valued at approximately $73.52 million. The company is broadly seen as a “Moderate Buy” by analysts, with an average target price of $95.75, and recently announced a dividend of $1.595 per share. Other institutional investors like Primecap Management Co. CA and Franklin Resources Inc. have also recently adjusted their positions in the biopharmaceutical company.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes